PubRank

Jan Westin

Author PubWeight™ 30.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International staging system for multiple myeloma. J Clin Oncol 2005 11.29
2 Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006 1.68
3 Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008 1.68
4 UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009 1.64
5 Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 2010 1.57
6 Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010 1.20
7 Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006 1.11
8 Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004 1.04
9 Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013 0.98
10 A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 2003 0.96
11 Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. Eur J Haematol 2005 0.91
12 Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer 2008 0.89
13 Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. Hematol J 2004 0.86
14 Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature. Ann Hematol 2008 0.83
15 Physicians as clinical directors: working conditions, psychosocial resources and self-rated health. Occup Med (Lond) 2004 0.83
16 MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer 2004 0.82
17 Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004 0.81
18 High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation. Br J Haematol 2004 0.78
19 Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. Eur J Haematol 2011 0.77
20 TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. Int J Med Sci 2008 0.76
21 Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care. Eur J Haematol 2005 0.75
22 [Swedish executive officers' frustration over working conditions]. Lakartidningen 2005 0.75
23 [Diagnosis and follow up of patients with small M components. With the view to avoid transformation to malignant disease]. Lakartidningen 2010 0.75
24 [Constant fear of liability reporting in physicians' everyday work. Impressions from interviews with physicians in Western Gotaland]. Lakartidningen 2003 0.75